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Introduction 
 
Illegal substance abuse is a growing problem, especially in 
young adults, including women of childbearing age. 
Therefore, knowledge of the effects of drug abuse during 
pregnancy is important, in order to correctly counsel the 
parents and to know how to manage the newborn baby. For 
evident reasons knowledge on this particular problem 
relies on animal experiments and reports on human 
observations. In this manuscript we describe the long term 
outcome of children after intra-uterine exposure to illegal 
substances. 
 
Marihuana is the most widely used drug in the Western 
world and the favorite drug used during pregnancy. In 1964 
Gaoui and Mechoulam found tetrahydrocannabinol (THC) 
to be the most psycho-active substance in marihuana. In 
1988 Devane et al confirmed the presence of an 
endocannabinoid system in the human body. Cannabinoid 
receptors are present in several tissues: brain, placenta, 
uterus, ovaria, and in the foetus. Among others, 
endocannabinoids play an important role in the 
progression of pregnancy and in the plasticity of cerebral 
synapses. Exogenous THC binds to the receptors longer 
than the natural endocannabinoids, thereby causing 
pathophysiological changes. Tetrahydrocannabinol crosses 
the placental barrier and is detectable in the blood of the 
foetus. As far as we know, THC is not teratogenic [1]. After 
intra-uterine exposure to THC, the risk of sudden infant 
death syndrome (SIDS) is raised. Tetrahydrocannabinol is 
secreted into breast milk and ingested by the baby. 
Prolonged exposure to THC by breast feeding may influence 
neuromotor development of the baby. From the age of 3 
years on, children may suffer from cognitive disorders 
(short term memory, verbal reasoning, concentration 
deficits, abstract thinking) and behavioural problems 
(hyperactivity, impulsivity, more criminal behaviour), that 
persist into adulthood [2]. As early as at the age of 10 years, 
symptoms of depression may emerge, evolving towards a 
full-blown clinical psychiatric picture. Epidemiologic 
studies suggest a relationship between intra-uterine 
exposure to marihuana and the development of acute non-
lymphoblastic leukemia at child age. Adolescents who have 
been exposed to THC antenatally are at higher risk of 
addiction to nicotine and marihuana. Exposure of the 
developing foetal brain to THC causes a rise in the number 
of cannabinoid receptors in the brain, making the adult 
brain more susceptible to the addictive effect. Genetic and 
environmental factors may play a role as well. 
 
The main substance in an ecstasy tablet is 3,4-
methylenedioxymetamphetamine (MDMA). A single 
exposure during pregnancy without maternal toxicity is not 
teratogenic [3]. In cases of repeated antenatal exposure, 
more cardiovascular defects (ventricular and/or atrial 
septal defects), musculoskeletal abnormalities (clumb 
feet), prematurity, low birth-weight and small for 
gestational age babies [4]. Experiments in rats indicate a 
higher risk of long term disturbances in learning capacities 
and memory after 3rd trimester exposure [5]. The ‘Drugs 
and Infancy Study’ found that babies from young mothers 
who used MDMA during the 1st trimester of pregnancy 
showed a severely delayed psychomotor development [6].  
 
As far as we know the use of opioids during pregnancy has 
no teratogenic effect [7]. The risk of SIDS is raised times 4 
to 5. The long term consequences for the child are 
presumably determined by socio-economic factors. 
Antenatal exposure to opiates in animals reduces cortical 
neuronal density and dendritic and axonal ramifications. 
The significance in humans of these findings is not clear. 
There is a higher risk of delayed psychomotor development 
and behavioural disturbances during the first years of life. 
 
Cocaine is a neuro-excitatory substance that causes 
abnormal behaviour with tremor, dystonic movements, 
irritability, abnormal sleeping pattern, poor feeding 
(newborns may need gavage feeding for days or weeks), 
vomiting, diarrhoea, fever, sneezing, high pitched cry, 
extreme sucking reflex, hyperactive Moro reflex, tachypnea, 
hypertonia, rarely convulsions [8-10]. The clinical picture 
is caused by a direct neuro-excitatory effect rather than 
abstinence. Cocaine use during pregnancy has been 
associated with prematurity, intra-uterine growth 
retardation (IUGR), microcephaly and a spectrum of 
abnormalities, caused by vascular dysruption sequence  
                             doi: 10.39127/IAPN:1000110 
           Smets K.  In Arch Pedia Neon: IAPN-110 
 
International Archives of Pediatrics & Neonatology 
                    In Arch Pedia Neon:  2020; Issue 2                                                                                                                                                                                                          Page: 1|3 
                                                                                                                           
   
Citation: Smets K (2020) Long Term Consequences of Illicit Drug Use During Pregnancy. In Arch Pedia Neon: IAPN-110. 
 
[8,11]. A higher incidence (6,5 %) of cardiovascular 
anomalies has been reported, such as peripheral 
pulmonary stenosis, patent ductus arteriosus, ventricular 
and atrial septal defects. Transient ST-segment elevation on 
electrocardiogram (ECG), marker of transient myocardial 
ischemia, has been documented. Children who have been 
exposed to cocaine antenatally are at higher risk of 
necrotising enterocolitis, with rather late onset of disease 
[12]. Breast feeding is prohibited: ingestion of cocaine with 
the mother’s milk carries the risk of acute intoxication, 
manifested by vomiting, diarrhoea, irritability and 
hypertension [13]. Information in literature on the long 
term consequences of antenatal exposure to cocaine is 
inconsistent. Children with microcephaly at birth do not 
show catch up growth of their head circumference at 2 
years of age and suffer from psychomotor retardation. 
Reports on cognitive-, motor-, speach- and behavioural 
development give inconsistent information [9]. Boys would 
be more prone to motor sequelae than girls. Some authors 
found a dose-respons effect. A prospective study in 219 
children, followed from the 4th month of gestation, did not 
find any problems with global cognitive development, 
learning capacities or memory at age 15 years [14]. 
However, first trimester prenatal exposure to cocaine was 
significantly related to delinquent behaviour, reduced 
problem solving capacities and abstract reasoning. At age 
15 years, children had a lower body weight, shorter stature 
and smaller head circumference. 
 
We found only 1 case report on the use of ‘liquid ecstasy’ 
(gammahydroxybutiric acid) during pregnancy [15]. Long 
term outcome is not described. The same accounts for 
lysergenic acid diethylamide [16]. 
 
Neonatal abstinence syndrome (NAS) is present in 60-80 % 
of babies whose mother used methadone and usually starts 
on day of life 3, but may ensue after 4 weeks as well [17]. 
Hyperphagia (> 190 to 290 mL/kg/day) is a marker of 
higher metabolic demands during NAS and is not associated 
with more weight gain or gastro-intestinal disturbances 
[18]. On the contrary, there is higher risk for excessive 
weight loss, especially in breast-fed children [19]. It takes 
more time for babies to regain their birth-weight. 
Methadone intake is a well known cause of long QT in 
adults. Clinically significant long QT in a neonate after 
antenatal exposure to methadone has been described [20]. 
Bradycardia or irregular heart rythm in a neonate whose 
mother took methadone during pregnancy has to be taken 
seriously and documented by an ECG. Flash visual evoked 
potentials may be abnormal in the 1st 2 weeks of life [21]. 
Concomitant use of benzodiazepines might contribute to 
that finding. It is not yet clear whether these changes are 
transient effecs of methadone and/or other substances still 
circulating in the blood of the newborn, or the consequence 
of a teratogenic exposure with long term consequences for 
visual function. Breast-feeding is allowed, even with higher 
doses (> 40 mg/day) of methadone [22]. The quantity of 
methadon ingested by the neonate will not suffice to 
prevent the NAS, but there are indications that the course 
might be more mild [19]. Long term consequences are 
probably determined by socio-economical factors. 
Although birth-weight is usually regained at a later time, 
further growth is usually not problematic. 
 
Buprenorphine is a semi-synthetic thebaïne derivative, that 
is inceasingly used instead of methadone for treatment of 
opioid dependent pregnant women [23]. Neonatal 
abstinence syndrome occurs in more than 50% of cases, but 
is usually rather mild [24-26]. There is no relationship 
between maternal dose and the severity of NAS. Treatment 
is not always indicated and, if necessary, morphine is 
administered. Buprenorphine is secreted in breast milk, 
probably only in small amounts . Breast feeding is allowed 
as it may diminish the need for treatment of NAS. Prenatal 
exposure to buprenorphine raises the risk of SIDS, probably 
only in cases of suboptimally treated NAS [23]. 
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